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Maintaining active interactions with the broad external scientific community is vital for FDA to fulfill its 
expanding public health mission.  It is essential for the Agency to be well positioned to address 
emerging areas of regulatory science and rapidly advancing technologies.   
Scientific engagement also helps FDA accomplish its mission by increasing awareness of FDA’s 
responsibilities and helping with the Agency’s critical recruitment and succession planning needs.  FDA 
uses a range of mechanisms for scientific exchange.  The Subcommittee was charged with considering: 
a. how FDA can improve its interface with the outside scientific community, particularly regarding 
public-private partnerships (PPPs) and fellowship programs and 
b. how the Reagan-Udall Foundation for FDA (RUF) can support both of these areas. 
Public-Private Partnerships  
The Subcommittee found that PPPs provide a valuable approach to inform and advance persistent and 
emerging areas of science and technologies that affect regulatory science.  At the same time, the issues 
of potential or real conflicts must always be recognized in PPPs, and transparency and external review 
are essential.  The Subcommittee found that: 
• FDA should take a strategic approach, including needs assessments, to determine whether the 
PPP mechanism is well suited to address a specific public health and regulatory science priority 
under FDA’s purview.   
• FDA Centers are best positioned to identify specific priority areas and should have the flexibility 
to determine the appropriate mechanism to address their scientific engagement needs.   At the 
same time, the Office of the Chief Scientist should create an inventory of FDA’s PPPs, capturing 
and sharing best practices, providing assessment tools to evaluate PPPs, and working to 
identify new opportunities.   
• RUF is well situated to further assist FDA with developing needed PPPs.  RUF should work with 
FDA to develop a regulatory science needs assessment and address clear priorities from FDA. 
 
Fellowships 
Diverse fellowship programs are used across FDA to promote scientific exchange, to support training, 
and to serve as recruitment and succession planning tools for FDA.  The Subcommittee found that: 
• The types and roles of the various FDA fellows should be reviewed and clarified, including 
tracking the career paths and future productivity of FDA fellows.   
• The use of the fellowship mechanism to support technical staff needs at FDA should be 
discouraged, however any modifications must be linked with increased flexibility and expanded 
authorities in the hiring process.    
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• A consistent and functional approach respecting both access to Commercial Confidential 
Information and policies on inherently governmental activities is critical to enhance fellows’ 
training experience and meet FDA needs.   
• The addition of a new flexible FDA Intramural Research Training Award, a separate track in the 
Commissioner’s Fellowship Program, and new RUF fellowships would provide a suite of 
programs to recruit trainees across the continuum from undergraduate students to senior 
scholars.   
• A phased approach should be initiated to develop RUF fellowship programs, starting with 
evaluating and implementing a senior scholars fellowship.    
• In addition to administrative and logistical challenges, RUF’s ability to raise and sustain funding 
for these programs will be a crucial issue to address.  Ultimately, RUF fellowships can provide a 
vital program to complement a portfolio of FDA fellowships. 
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Background and Charge 
Background 
FDA, like other federal agencies, regularly engages the expertise of the external scientific community to 
advance the Agency’s public health mission.  Public-private partnerships (PPPs) are one mechanism 
through which this engagement is often accomplished.  PPPs enable FDA to work with industry, 
academic institutions, public interest groups, and other entities.   
PPPs can help advance FDA’s public health mission by a) working to fill the knowledge gaps that may 
delay or impede the development of treatments for diseases and b) harnessing outside expertise to 
answer challenging scientific questions about, for example, cutting-edge medical products and food 
safety issues.   
Similarly, the intramural research that FDA conducts provides a mechanism for engaging outside 
scientists at all stages of experience and training by providing temporary employment, instruction, and 
professional development through fellowship programs. Such fellowships are vital to developing the 
next generation of regulatory scientists and reviewers.    
 
Charge 
Goal: FDA seeks input from the Science Board on how the Agency can improve its interface with the 
outside scientific community, including ways in which FDA can better focus and manage such efforts.  
Questions: 
1) When is an FDA goal most appropriately addressed through participation in a PPP and what 
factors (capabilities, expertise, etc.) should FDA consider when establishing or using PPPs?  For 
what areas of science would PPPs be most beneficial to FDA?  What types of PPPs does the 
subcommittee believe FDA should explore? 
2) The Reagan-Udall Foundation (RUF) is an independent 501(c)(3) not-for-profit organization 
created by Congress to support FDA’s mission by advancing regulatory science and research. 
RUF leads and collaborates on programs, projects, and other initiatives that further its mission 
in support of FDA. How can FDA better use the Reagan-Udall Foundation to meet the needs 
identified in question 1? 
3) In its 2015 report, Mission Possible: How FDA Can Move at the Speed of Science, the Science 
Board suggested numerous scientific areas in which FDA should invest. How can fellowships 
address the scientific areas mentioned in the report?  Please address this with respect to Senior 
Fellows, Commissioner’s Fellows, Early-Career Fellows, and other types of fellows.  
4) Another initiative by which RUF can contribute to FDA’s mission is through RUF’s support of 
FDA Fellows. In accepting RUF-supported Fellows, FDA will apply its ethics policies and 
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principles to the funding source and the Fellows’ activities. Are there any other considerations 
that FDA should have in accepting Fellows from RUF?  
Process 
Subcommittee Formation and Review of Materials 
The Subcommittee was established in May 2016 and was composed of the following members: 
Anthony Bahinski, PhD, MBA, FAHA 
Global Head, Safety Pharmacology 
Mechanistic Safety & Disposition, In Vitro/In Vivo Translation 
R&D Platform Technology & Science 
GlaxoSmithKline 
 
Maria C Freire, PhD 
President and Executive Director 
Foundation for the NIH 
 
Mark R. McLellan, PhD  
Vice President for Research 
Dean of the School of Graduate Studies  
Utah State University 
 
Bruce M. Psaty, MD, PhD, MPH 
Co-director, Cardiovascular Health Research Unit 
Professor, Medicine & Epidemiology  
University of Washington  
 
Dan M. Roden, MD 
Professor of Medicine, Pharmacology, and Biomedical Informatics 
Vanderbilt University School of Medicine  
Senior Vice-President for Personalized Medicine 
Vanderbilt University Medical Center 
 
Scott J. Steele, PhD 
Subcommittee Chair 
Director, Regulatory Science Programs  
Deputy Director, Goergen Institute for Data Science 
Associate Professor, Public Health Sciences 








A site visit was held on June 16, 2016, at FDA (White Oak).  The agenda is included in Appendix A.  The 
visit included critical overviews and discussions from key leaders from across FDA and the Reagan-Udall 
Foundation for FDA.  
Key Findings  
A strong scientific foundation and the exchange of scientific knowledge are critical for FDA to carry out 
its mission to protect and promote the public health.  Indeed, the FDA Science Board has been 
particularly focused on approaches that would enable FDA to ensure that it is able to conduct its 
scientific and regulatory mission.  To that end, the Science Board has released a number of reports 
providing recommendations on these topics (FDA Science Mission at Risk, 2007; Mission Possible: How 
FDA Can Move at the Speed of Science, 2015).   
FDA has launched several plans and initiatives to advance regulatory science and to enhance external 
scientific engagement (Advancing Regulatory Science for Public Health, 2010; Advancing Regulatory 
Science at FDA, 2011).  These plans have resulted in informal and formal activities and partnerships led 
by FDA groups, Offices, Divisions, and Centers.   
The Office of the Chief Scientist has specifically led scientific engagement initiatives designed to cut 
across FDA Offices and Divisions (e.g., the FDA Science Forum, Commissioner’s Fellowship Program, 
Centers of Excellence in Regulatory Science and Innovation program, and the Regulatory Science Broad 
Agency Announcements).  These activities can take the form of conferences and workshops, 
Cooperative Research and Development Agreements (CRADAs), external grants, scientific exchanges, 
establishing new intramural programs, and the formation of PPPs.   
Some Centers have identified clear roles for PPPs that are relevant to the products they regulate to 
address their scientific needs.  Other Centers/Offices use different mechanisms, such as workshops and 
scientific conferences to engage the scientific community and exchange information.   
Public-Private Partnerships 
Value and Strategic Approach to Developing PPPs 
PPPs have the potential to provide a powerful mechanism to collaboratively leverage resources and 
expertise across a broad range of stakeholders with a common interest, an approach that is likely to 
benefit all partners and enhance public health.  These PPPs are particularly well suited to address and 
inform enduring and emerging science and technologies that may affect regulatory science, promoting 
information-sharing among relevant parties.   
It is critical for FDA to be prepared for emerging technologies and to exchange knowledge with leaders 
in these fields and technology areas.  The Subcommittee found FDA’s approach to using PPPs at several 
levels to be quite diverse and robust (Table 1).  The Centers have developed thoughtful approaches to 
design, implement, and review PPPs.  This process and existing models should be shared across FDA. 
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Table 1.  Examples of active FDA public-private partnerships 
Organization Program/Project 
Critical Path Institute (CPI) Coalition Against Major Diseases Consortium (CAMD) 
Predictive Safety Testing Consortium (PSTC) 
International Neonatal Consortium (INC) 
Foundation for the NIH (FNIH) Biomarker Consortium (BC) 
Clinical Trials Transformation 
Initiative (CTTI) 
Large Simple Trials 
Central IRBs 
Medical Device Innovation 
Consortium (MDIC) 
Patient-Centered Benefit-Risk Assessment 
Computer Modeling & Simulation 
America Makes Advanced Manufacturing of Biomedical Devices from 
Bioresorbable Metallic Alloys for Medical Applications 
Reagan-Udall Foundation for the 
FDA (RUF) 
Innovation in Medical Evidence Development and 
Surveillance (IMEDS) 
 
Safe Harbor Requiring Transparency and Review 
PPPs established through a 501(c)(3) mechanism can provide a safe harbor to share information and 
address research areas in the pre-competitive space.  However, even in an apparent safe harbor 
situation, such as the 501(c)(3), the issues of potential or real conflicts must always be recognized and 
managed.   
In the setting of a PPP, FDA staff will interact with individuals, for example, from academia, patient 
advocacy groups, and industry, who may have a real or perceived agenda in terms of seeing particular 
policies, actions, technologies, or methods moved forward and others not promoted.  For example, 
individuals from academia may have methods they have developed that they are interested in seeing 
widely adopted.  Likewise, industry members may have an interest in seeing approaches developed 
that reduce regulatory requirements for drug approval.   
In the setting of moving forward selected aims, the influence may be subtle and appear in the form of 
unexamined assumptions.  Further, the level of personal interactions at these venues can carry with it a 
risk of perceived enhanced access.  These situations should be identified up front to ensure 
transparency.  An independent review by non-affiliated individuals should be considered as routine to 
address any perceived and real conflict as these PPPs issue recommendations.  
Reagan-Udall Foundation for the FDA 
The Reagan-Udall Foundation for the FDA (RUF) is an independent 501(c)(3) entity created by Congress 
via the Food and Drug Administration Amendments Act of 2007 (FDAAA 2007) to advance the 
regulatory science and public health missions of FDA.  Similar to the Foundation for the National 
Institutes of Health (NIH) and other congressionally mandated foundations that support particular 
federal agencies, RUF is uniquely positioned to support the mission of FDA and to work with FDA to 
convene diverse stakeholders from government, industry, academia, and patient groups to address 
regulatory science needs.   
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RUF activities can take multiple forms: creating PPPs, developing and providing awards for specific 
projects, convening workshops and meetings, and establishing training programs, among others.  
Although the statute provides for a modest level of FDA direct support to RUF, the foundation can and 
must solicit external funds to support its initiatives.   
The ability to raise external funds provides RUF with significant opportunities, independence, and 
flexibility to assist FDA in its mission, particularly given the challenges with the current federal budget 
and FDA’s limited resources to support new programs.  Although FDA should lead the identification of 
scientific, regulatory, and human resources needs and determine which projects/programs it presents 
to RUF for consideration, FDA cannot discuss funding needs with potential donors.   
Bilateral conversations between companies and agencies on programs in which they are potential 
funders create problems of perception and undue influence. The need for transparency and 
independence is critical.  The law includes several provisions to ensure independence and public 
accountability.  
RUF, therefore, plays a unique role to help facilitate these PPPs and catalyze scientific collaborations 
and exchanges.  RUF also has the ability to embark on projects and programs that FDA does not bring 
to the table but that support FDA’s mission. Any project this mechanism develops would also require 
transparency and independent review, and should still be developed in close coordination with FDA to 
ensure it aligns with their needs and mission and to avoid redundancy with existing programs.   
Challenges 
Despite the provisions to ensure transparency and independence, there were Congressional concerns 
and delays in the initial establishment and funding of RUF, contributing to significant barriers to 
launching projects and challenges to ensure stable RUF leadership and staffing. 
 
The law outlines a process for FDA to communicate priorities to RUF and for RUF to develop a 
regulatory science needs assessment.  Clearly this process needs to be undertaken in a more proactive 
and robust manner.  Challenges in funding and staffing for RUF remain a significant barrier in selecting 
and launching projects, preventing it from realizing its full potential.  Recent steps have been taken to 
enhance some of RUF’s operations, including: 1) the recent selection of a new Executive Director; 2) 
expansion of the RUF Board; and 3) renewed efforts to raise funds to support RUF initiatives.   
Fellowships 
A range of fellowship programs is used across FDA to promote scientific exchange, support training, 
and as recruitment tools for FDA (Table 2).  Trainees also serve as future ambassadors, who will go into 
academia, industry, government or other sectors with knowledge of FDA and potentially become future 
partners in product development and in addressing public health issues.   
The recruitment of fellows and other trainees also plays a critical role in FDA’s succession planning, 
increasing the availability and interest of professionals knowledgeable and capable of assuming a range 
of roles at FDA.  One prominent program is the Commissioner’s Fellowship Program, which includes 
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both substantial course work and hands-on regulatory science experiences at FDA.  Another potential 
but not fully realized role for fellowships is the opportunity for senior leaders in academic medicine to 
receive support for spending time at FDA, furthering their own understanding of issues in regulatory 
science, and bringing their experience and expertise to FDA.  
Table 2.  List of primary FDA fellowship programs for post-graduate trainees and 
scholars   
Mechanism Program 
Example  
Eligibility Program Goals, Requirements, and 
Outcomes 
Title 42 209(g) 














within 7 years 
of degree 
Goals  
1. Attract top-tier scientists to FDA to address 
regulatory science issues through mentored 
projects of high priority to the Agency  
2. Provide regulatory science training  
3. Serve as a potential recruiting tool.  
 
Requirements 
1. Mentored project 
2. Courses 
3. Regulatory experiences.  
Title 42 209(g) 









Within 7 years 
of degree 
Provides flexible mechanism for the temporary 
employment, training and professional 
development of promising research/regulatory 
















1. Continue their research/education 
2. Enhance professional development in specific 
areas 
3. Become familiar with research areas 
4. Become interested in future careers in fields 










Access to CCI 
 






within 5 years 
of degree 
Overarching objectives for program 
1. To train a cadre of scientists in research and 
research-related regulatory review, policies, 
and regulations to develop a skill set bridging 
two disparate processes.  
2. To build awareness of regulatory 
requirements into the early stages of product 
development processes. 
3. To improve planning throughout research 
and regulatory review to facilitate the 
movement of novel approaches from the 
bench to the community. 
4. To facilitate the movement of drugs, 
biologics, and devices from basic bench 
science to commercialization.  
Title 5 










Within 2 years 
of degree 
Provides employment opportunities through 
meaningful training and career development 
opportunities for individuals who are at the 











Gain experience and expertise to further define 
and develop the field of regulatory science as it 
relates to the regulation of tobacco products 
CCI: commercial confidential information 
One significant source of fellows for FDA that is also used by other Federal departments and agencies is 
the Oak Ridge Institute for Science and Education (ORISE) program.  The Department of Energy (DoE), 
via a contract to the nonprofit Oak Ridge Associated Universities, supports the ORISE program to 
develop science, technology, engineering, and mathematics (STEM) training experiences for students, 
postgraduates and faculty.   
The FDA ORISE Research Program was established via an interagency agreement with DoE.  It is the 
largest program (~80% of the nearly 1,400 fellows at FDA) used across FDA’s Centers and Offices to 
bring students, post-graduates, and faculty to FDA to support scientific exchange and professional 
development.  Importantly, this program permits participation of foreign nationals, sponsoring visas for 
fellows.  
Although all of the programs outlined in Table 2 officially allow fellows and trainees access to 
commercial confidential information (CCI) generally required for regulatory review activities, only Title 
42 and Title 5 fellows who are FDA employees may perform inherently governmental activities.  
Inherently governmental activities are interpreted to include representing FDA and obtaining training 
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experiences, such as serving as a review author and/or presenting at an Advisory Committee meeting.  
In practice, the Subcommittee found that there are varying interpretations as to which fellows can 
access CCI and potentially participate in the different aspects of regulatory review.  Specifically, the lack 
of a clear and consistent approach to defining inherently governmental activities hampers these 
training programs.  
A recent review of the entire ORISE program (GAO-16-128: Published: Jan 20, 2016), issues of defining 
inherently governmental activities, and efforts to ensure consistency in the program’s use is creating 
significant challenges for FDA in planning and addressing fellowship and internship needs.   
One challenge with the FDA ORISE program is the lack of detailed outcome measures and an 
assessment of how the program is being used across FDA.  Discussions during the site visit raised the 
possibility that the FDA ORISE Program was also being used to address pressing, broader research and 
technical staff needs.  Putting in place measures to assess program outcomes would be a way to 
determine whether and to what extent these issues may exist.  
Attracting mid- or senior-level scientists and other professionals for a fellowship or rotation is an FDA 
priority and challenge, although the specific need and level of interest for these scientists was difficult 
to gauge.  The previously proposed Alzheimer’s fellowship initiated by RUF is an informative example 
that encountered challenges and provides lessons learned to create an effective model for developing, 
funding, and launching these programs, including: 
a) accurate assessment of the level of interest from potential candidates 
b) perceived conflicts of interest based on the program sponsor (even if a foundation) 
c) the need for a key advocate and mentor at FDA 
d) the ability to identify a relevant mid- to senior-level professional who is able to accommodate 
the funding structure 
e) timing and other logistical constraints of a sabbatical at this stage in their career 
f) difficulty with the contract mechanism, and 
g) issues with sustaining a training program, such as this, once it is launched 
As highlighted in previous reports, the human resources process does not currently function in such a 
way as to provide increased flexibility in salaries, hiring authorities, and merit increases.  Conflict of 
interest restrictions and other processes at FDA also have an impact on the ability to recruit and retain 
trainees and fellows (Mission Possible: How FDA Can Move at the Speed of Science, 2015). These 
human resource hurdles appear at times to contribute to the use of fellowship awards to support the 
hiring of technical staff, rather than to create genuine training opportunities.  
Potential for RUF Fellows  
To date, RUF has not used its statutory authority to establish fellowship programs so as to place a range 
of professionals who are not employees of regulated companies at RUF, academic or scientific 
institutions, or FDA (FDAAA 2007).  The statutory authority is designed to foster regulatory science 
training and scientific exchange, and the law grants RUF fellows the ability to access commercial 
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confidential information (CCI).  However, they cannot perform inherently governmental activities 
during this period.  The ability of RUF to use diverse funding sources to support training programs 
makes RUF fellowships particularly attractive.   
Recommendations 
FDA Strategic Approach to Scientific Engagement 
 
Figure 1.  Strategic view and approach to FDA’s diverse mechanisms for scientific engagement 
 
To fulfill its requirements, FDA effectively uses a range of mechanisms for engaging with the scientific 
community.   Centers should continue to have the flexibility to choose the optimal methods to meet 
their requirements.  FDA should continue to define public health and regulatory science priorities 
under its purview, assess its needs based on these areas and existing FDA programs/expertise 
(intramural and extramural), and then determine its requirements/gaps.  Meeting these requirements 
can be achieved through various mechanisms, such as: grants, contracts, cooperative research and 
development agreements (CRADAs), Material Transfer Agreements (MTAs), workshops/meetings, PPPs, 
and, in some cases, developing new intramural programs (Figure 1). 
Public-Private Partnerships 
PPPs should be considered as one of many potential mechanisms for FDA to carry out its mission to 
protect and advance public health (Figure 1). PPPs likely work best for enduring problems and areas of 
emerging technologies, whereby diverse partners with a common goal are needed to jointly pool their 
resources and leverage unique expertise.   
FDA has already established several valuable PPPs; future PPPs should address standards and 
approaches needed for implementing a range of new and emerging technology areas (e.g., next 
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generation sequencing, 3D printing, and mobile apps).  The resulting guidance documents, methods 
papers, and relevant data and findings generated from demonstration projects will advance key areas 
of regulatory science.  Throughout this process, attention needs to be paid to the potential issues of 
perceived and real conflicts of interest and enhanced access discussed above.   
Role for the Office of the Chief Scientist in Supporting PPPs 
The Office of the Chief Scientist (OCS) should play a key role in creating an inventory of FDA’s PPPs, to 
accumulate relevant experiences, capture and share best practices, and provide assessment tools that 
can help the Centers/Offices to evaluate the return on investment and risk/benefit for their 
participation in PPPs. Using these best practices and assessment tools, OCS would advise Centers as 
they consider new PPPs or evaluate existing partnerships.   
The Senior Science Council could provide an effective venue to provide this input, as well as increasing 
awareness and coordination with other Centers and Offices that might be considering (or already have 
existing) PPPs with similar goals.  OCS can also support a broader portfolio review of PPPs to advise the 
Commissioner on potential gaps/needs.    
FDA Centers’ Use of PPPs and Other Mechanisms for Scientific Engagement 
The Subcommittee recommends that the Centers are best positioned to identify priorities and 
determine the appropriate mechanism to address their scientific engagement needs, whether via PPPs, 
workshops, scientific conferences, or other mechanisms.  Centers/offices should have the flexibility to 
develop a broad range of PPPs or other methods of engagement that address relevant public health 
priorities and their specific needs.  When using PPPs, FDA should ensure that those PPPs are addressing 
clear needs and are being evaluated.  OCS can provide support (as noted above) and maintain a 
broader inventory and knowledge of the full portfolio of PPPs. 
RUF and PPPs 
Unique Role 
RUF is well situated with unique authorities and the mission to address FDA’s PPP needs, while FDA will 
continue to use a range of other effective PPPs that the Centers have identified.  RUF has significant 
potential and should be supported and leveraged.  Sustained funding will be critical for RUF to achieve 
its goals.  A top priority for RUF should be engaging donors and funders to provide support for urgent 
projects.  RUF will need to explore a range of funding initiatives, and in considering the source of 
external funds and how they will be directed, it is vital to ensure transparency and address potential 
conflicts, enhanced access, or undue influence for funders and donors.  
Setting Clear Priorities from FDA 
FDA should ensure it is providing a needs assessment, setting clear priorities, and routinely providing 
this information to RUF.  FDAAA 2007 stipulates that RUF will conduct and update an assessment to 
“identify unmet needs in the development, manufacture, and evaluation of the safety and 
effectiveness, including post-approval, of devices, including diagnostics, biologics, and drugs, and the 
safety of food, food ingredients, and cosmetics, and including the incorporation of more sensitive and 
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predictive tools and devices to measure safety” 1 and that it will use this assessment to establish goals 
and programs (while reviewing existing and planned HHS programs) in close coordination with 
HHS/FDA.  This process should be implemented to set clear goals and recommended programs. 
 
Detailees to RUF 
FDA (and via other HHS agencies) should explore using additional detailees to temporarily assign 
federal employees to RUF for relevant scientific projects, training programs, and general administrative 
and project management assistance to help support RUF, particularly as it expands these efforts over 
the next few years.  The authorities to provide detailees are outlined in FDAAA 2007. 
Fellowships 
Clarifying Roles and Needs for Fellows and Other Trainees 
FDA should establish a mechanism to collect data on fellows and more clearly evaluate the current 
roles and outcomes of the fellowship programs.  A needs assessment should also be completed across 
FDA Centers to determine their requirements, goals, and capacity to support fellows.   
The Commissioner’s Fellowship Program appears to be one of the few fellowship programs that have 
data available to address these questions.  The FDA ORISE Research Program is addressing a broad 
range of FDA needs due to critical funding constraints and human resource hurdles.  Although some 
trainees are used for postdoctoral fellows and faculty rotations, the Subcommittee was informed that 
others appear to serve as technical staff and research scientists.   
As a short-term recommendation, FDA should address administrative, policy, and planning 
requirements related to the ORISE program, working within HHS and the DoE, as necessary.  As a next 
step, the diverse roles being addressed by the FDA ORISE Research Program should be more carefully 
analyzed and separated as necessary, to ensure that these programs are primarily being used to 
address training needs, in combination with the broader needs assessment outlined above.   
If the current fellowship programs are also used to address key technical staff needs and other roles, 
any changes must be combined with broader modifications to the hiring and recruitment policies and 
processes.  These broader changes to hiring practices have been identified previously and present 
significant challenges, but must be coupled with any modifications to the fellowship programs.  
Independent changes to the fellowship programs will create further gaps in technical staff needs. 
Additionally, as FDA recruits fellows and other trainees, FDA should also consider mid- to long-term 
succession planning to help address critical needs across the Agency.  
Consistent Approach to Commercial Confidential Information and Inherently Governmental Activities 
To enhance fellows’ training experience and meet FDA needs, fellows should generally have the ability 
                                                        
1 FDAAA 2007, Available at: 
http://www.fda.gov/RegulatoryInformation/Legislation/SignificantAmendmentstotheFDCAct/FoodandDrugAdministrationAm
endmentsActof2007/default.htm, accessed Oct. 25, 2016. 
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to access CCI and participate in aspects of regulatory review, at the discretion of the Agency, based on 
the fellows’ role and responsibilities.   
As a parallel example, in other government agencies, security clearances can be granted to fellows who 
are not federal employees in roles that require their access and contribution to the analysis of classified 
national security information, without fellows officially representing or making decisions on behalf of 
an agency.   
Given the significantly more complex nature of handling and analyzing classified information, FDA 
should explore and implement a process, including legislative initiatives, if necessary, whereby fellows 
who are not FDA employees can access and analyze CCI.  In this way they could contribute to regulatory 
review with the appropriate safeguards to ensure that they were not officially representing FDA. 
Conflicts of interest, real or perceived would also be addressed.  FDA should also use a consistent and 
reasoned approach and interpretation of inherently governmental activities.  These issues should be 
managed across FDA in a transparent and standard approach that addresses appropriate concerns, 
while ensuring a productive and beneficial training experience.   
A FDA Intramural Research Training Award 
To address the broader challenges concerning FDA’s ability to recruit trainees at the undergraduate, 
graduate, post-doctoral, and other levels, FDA should seek any required authorization to establish a 
robust and flexible Intramural Research Training Award (IRTA), similar to the IRTA program actively 
used by the National Institutes of Health’s (NIH) Institutes and Centers.   
NIH has a centralized and successful IRTA program as part of a broad range of training initiatives 
coordinated by the NIH Office of Intramural Training and Education.  Although this scale of activity may 
not be required, the IRTA and related intramural training programs would be a critical asset to support 
FDA.  As noted previously, it would be essential to ensure that any amended or new legislation, as 
necessary, permits trainees to have access to CCI and participate in aspects of regulatory review.  
Adequate funding plans to support the program must also be considered. 
The Commissioner’s Fellowship Program 
To provide additional flexibility for fellowship opportunities and to address FDA needs, an additional 
track in the Commissioner’s Fellowship Program (CFP) should be established.  The current CFP would 
continue with its additional focus on course work, while a second track would be established with a 
primary research or review focus.  This track would focus on a rotation in an FDA laboratory, a review 
group, or other relevant office.  The fellowship could be coupled with a university-based program (e.g., 
MS, Certificate, or KL2 program) and a previous report to the Science Board on the CFP recommended 
that FDA work with academic partners to establish the CFP as an experiential component of a formal 
degree program.  (FDA Commissioner’s Fellowship Program, 2015).While these would be targeted 
rotations as part of an academic program, there would be funding considerations to support the fellow 
during the actual period of the rotation at FDA.  Additionally, the overall CFP program requires 
increased and sustained funding support.  
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Use of Interagency Detailees 
To promote scientific exchange with other science and research agencies, FDA should engage federal 
detailees (bi-directionally) from other agencies (e.g., NIH, Center for Medicare and Medicaid Services, 
Centers for Disease Control and Prevention, and Department of Defense) that have active research 
programs and can provide additional opportunities for scientific engagement and professional 
development.  
The Researcher-Reviewer Role for FDA Personnel 
Centers have employed diverse approaches to maintain scientific awareness for their scientists, 
clinicians, engineers, and other professionals.  For example, there are many reviewers who maintain 
active research portfolios and there are many research scientists who support or provide consultations 
for the review process. Research ranging from discovery science to clinical research applied to solving 
FDA’s regulatory science questions helps reviewers acquire the most up-to-date knowledge that 
bolsters their study design, analytic and review skills, while also informing regulatory policy and 
decision making.  Centers should consider increasing these types of roles, including for junior scientists, 
as a way to ensure FDA scientists stay engaged in their professional fields as well as maintain 
professional relationships with the external scientific community.  
Critical Role for RUF to Support Fellowships in a Phased Approach 
RUF should play a vital role in supporting fellowships at FDA by using its unique authorities.  Based on 
FDA’s strong desire to specifically attract later-career fellows, the Subcommittee believes an initial area 
for RUF to concentrate its efforts on would be piloting fellowships for senior scientists.   
RUF should begin assessing the interest of relevant mid- to senior-level subject matter experts (SMEs) 
in spending time as senior fellows/scholars at FDA.  This survey could begin with current Special 
Government Employees (SGEs) serving on FDA advisory and other committees.  RUF would gather 
comments and feedback on issues of interest in a fellowship opportunity, ideal timing and duration, the 
topics and areas of interest, and funding needs, among other questions.  This could include a public 
workshop to gain broader feedback and engagement, based on the results of the survey.   
In addition to academia, perhaps senior fellows could also come from patient advocacy groups, and 
industries that are not regulated by FDA.  Other technology sectors could potentially participate to 
provide different perspectives.  The information from the survey and workshop, tied to a clear outline 
of FDA Centers’ goals and needs, would be helpful for RUF to both proactively and opportunistically 
identify external support to fund a successful new RUF senior fellowship or scholars program at FDA. 
This initial senior scholars fellowship would serve as a pilot to meet an FDA need, while also 
determining how to address a number of challenges to expanding programs, including issues of 
identifying FDA mentors and prospective trainees, timing and logistics of placing fellows, and RUF’s 
ability to raise and sustain funding for these programs.  Identifying stable funding sources for even an 
initial small number of fellows remains a major challenge.   
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After the senior fellow program is successfully launched, RUF could begin applying this model and 
lessons learned to support other broader fellowship opportunities at FDA.  This might include 
evaluating future support for the CFP.  More broadly, RUF and FDA can help create a cohort of fellows 
and explore team-based fellowships that reinforce core competencies, along with research experiences 















Figure 2.  Comparison and alignment of current and proposed FDA fellowships (*Indicates newly proposed 
programs). Selected fellowship programs are represented by bars mapped against the corresponding career 
stage/eligibility for the indicated program.  
 
 
Develop RUF Fellowships as Part of a Portfolio of Fellowships 
FDA should actively engage RUF in developing the RUF fellowships to ensure they complement existing 
programs, providing a menu of fellowships with different participants and designed to address diverse 
goals.  Ultimately, maintaining a broader suite of programs that provide training opportunities across 
the continuum of career stages will allow for a flexible approach to meet FDA’s requirements (Figure 2).  
This approach will ensure FDA maintains a level of control to address its needs, while providing 
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